Eli Lilly's orforglipron shows strong obesity, diabetes results

Chugai Pharmaceutical, creator of orforglipron, announced positive top-line results from Eli Lilly's phase 3 ATTAIN-2 trial for the oral GLP-1 receptor agonist in adults with obesity or overweight and type 2 diabetes. The study showed all three doses of orforglipron met primary and key secondary endpoints at 72 weeks, achieving statistically significant weight reduction and clinically meaningful HbA1c improvements.

Patients taking the highest dose (36mg) of orforglipron experienced an average weight loss of 22.9 pounds, or 10.5%, compared to 2.2% (5.1 pounds) in the placebo group. HbA1c levels decreased by 1.3% to 1.8% across dosage groups from a baseline of 8.1%, with 75% of patients on the highest dose reaching the ADA's diabetes threshold of 6.5%.

Orforglipron's safety profile was consistent with established GLP-1 receptor agonists, with the most common adverse events being gastrointestinal and generally mild to moderate. Discontinuation rates due to adverse events ranged from 6.1% to 10.6% across orforglipron groups, compared to 4.6% for placebo.